Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Donna McMenamin is one of thousands of breast cancer patients in the UK caught up in a disagreement over costs between the ...

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

“With the majority of breast cancer cases historically considered ... The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are ...

Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and ...